Clinical trials: Fatty Liver Disease
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
NAFLD in Adolescents and Young Adults With PCOS
This project focuses on an at-risk adolescent and young adult population who may gain long-term health benefits from detection of risk factors at a young age.
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02506946
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Columbia University
NASH - Nonalcoholic Steatohepatitis
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months.
- Trial name
- NCT03587831
- Testing
- Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Hyperinsulinemia, Insulin Resistance
Glycemic Effect of Diazoxide in NAFLD
The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver…
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Trial name
- NCT05729282
- Testing
- Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, FreeStyle Libre Pro
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT06947304
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Corcept Therapeutics
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Digoxin In Treatment of Alcohol Associated Hepatitis
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin…
- Conditions
- Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
- Trial name
- DIGIT-AlcHep (NCT05014087)
- Testing
- Intravenous digoxin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- Trial name
- NCT06108219
- Testing
- Miricorilant (Cohort A), Miricorilant (Cohort B)
- Where
- 77 sites in United States, India and 1 more
- Volunteers
- 175 people
- Sponsor
- Corcept Therapeutics
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-alcoholic Steatohepatitis
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis
The purpose of this study is to evaluate the efficacy and safety of berberine treatment on Non-alcoholic Steatohepatitis.
- Trial name
- EASYBEinNASH (NCT03198572)
- Testing
- Lifestyle intervention, Berberine
- Where
- 6 sites in China
- Volunteers
- 89 people
- Sponsor
- Fudan University
Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum…
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease, Hepatic Steatosis
- Trial name
- NCT06352697
- Testing
- Probiotic lysate (postbiotic and metabiotc)
- Where
- 5 sites in Ukraine
- Volunteers
- 52 people
- Sponsor
- Bogomolets National Medical University
MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis)
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
- Trial name
- NCT07581951
- Testing
- HSK31679
- Where
- China
- Volunteers
- 886 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-Alcoholic Fatty Liver Disease
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06133101
- Testing
- Standard Soy Milk, 2% Fat Cow's Milk
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Marialena Mouzaki
Nonalcoholic Fatty Liver
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.
- Trial name
- NCT07200934
- Testing
- Transcutaneous electrical stimulation (TENS), Mediterranean Diet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Celiac Disease, Metabolic Syndrome
Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents
metabolic syndrome and fatty liver is common in adolescents with celiac diseases. exercise may control these cardiovascular risk factors
- Conditions
- Celiac Disease, Metabolic Syndrome, Non Alcoholic Fatty Liver
- Trial name
- NCT07832994
- Testing
- walking exercise
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Alcohol-Related Liver Disease, Drug-Induced Liver Injury
Misocholic Tablets for Non-Viral Elevated Liver Enzymes
Elevated liver enzymes are common laboratory abnormalities that may result from alcohol-related liver disease, drug-induced liver injury, or non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07833514
- Testing
- Misocholic Tab, Silymarin (Silybum marianum)
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Hanoi Medical University
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis, Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
- Trial name
- NASH (NCT05011305)
- Testing
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Where
- 129 sites in United States, Argentina and 2 more
- Volunteers
- 189 people
- Sponsor
- Zydus Therapeutics Inc.
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Non-alcoholic Fatty Liver Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
- Trial name
- NCT07335198
- Testing
- Efimosfermin alfa
- Where
- New Zealand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline